AndhraNews.net
Home » Features » Health » Hepatitis B

Hepatitis B


About Hepatitis B

Hepatitis B death toll in Gujarat rises to 34
The Hepatitis B death toll in Modasa, Gujarat has risen to 34, with ten more deaths reported on Thursday. ANI

Hepatitis B medicines

  • Biostar Pharmaceuticals's Xin Ao Xing Oleanolic Acid Capsule, an over-the-counter (OTC) medicine for chronic Hepatitis B
  • Scientists from Second Military Medical University in Shanghai have revealed that mutations in the DNA of hepatitis B virus (HBV) might help predict which patients are at increased risk of developing liver cancer.

    Hepatitis B in News

    Curb Energy Consumption
    (Family Features) Water heaters are energy intensive appliances. In fact, they are the second largest energy user in the home, and as they age, they become less efficient, requiring even more energy.

    Before CEOs Pop the Question, They Need to Understand Why Most Mergers Fail and the Secret Behind Those That Succeed
    In 2014, companies around the world spent $3.5 trillion on mergers and acquisitions, and merger volume in 2015 is expected to be an all-time record.

    Novartis announces Phase III studies of Jakavi show disease improvement in patients with myelofibrosis and polycythemia vera
    Novartis International AG /Novartis announces Phase III studies of Jakavi show disease improvement in patients with myelofibrosis and polycythemia vera . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

    Molecular Diagnostics Market Worth $9.50 Billion by 2022: Grand View Research, Inc.
    The global molecular diagnostics market is expected to reach over USD 9.50 billion by 2022, according to a new report by Grand View Research Inc. Growing prevalence of chronic diseases and infections such as HPV and influenza is anticipated to be the key driver for molecular diagnostics market growth

    NCCN Collaborates With Bristol-Myers Squibb to Study PD-L1 Expression and Test Interpretation in Lung Cancer
    FORT WASHINGTON, PA--(Marketwired - November 30, 2015) - New molecules and pathways with pivotal functions in regulating the immune system have been discovered recently, providing new understanding of how tumor cells avoid the immune system

    SuperSonic Imagine to Highlight Advancement in Microvascular Imaging at Annual Radiology Meeting
    SuperSonic Imagine (EURONEXT PARIS: SSI) (FR0010526814), the highly innovative ultrasound company, announced today that its new microvascular imaging technology will be showcased at the 101st Scientific Assembly & Annual Meeting of the Radiological Society of North America

    GlobeImmune Announces Third Quarter 2015 Results and Corporate Highlights
    LOUISVILLE, CO--(Marketwired - November 13, 2015) - GlobeImmune, Inc. (NASDAQ: GBIM), a biopharmaceutical company focused on developing products for the treatment of cancer and infectious diseases based on its proprietary Tarmogen® platform, today announced its third quarter 2015 financial results and activities.

    SuperSonic Imagine to Showcase Its Non-Invasive, 60-Second Liver Assessment Exam as an Alternative to Biopsy
    SuperSonic Imagine (EURONEXT PARIS: SSI) (FR0010526814), the highly innovative ultrasound company, announced today that the clinical benefits of its ShearWave™ Elastography (SWE™) technology for non-invasive assessment of patients with chronic liver disease will be presented while attending the Liver Meeting® 2015

    Altimmune Chief Scientific Officer to Present at Two Premier Vaccine Conferences
    Altimmune, Inc. (formerly Vaxin Inc.), a clinical stage immunotherapy and vaccine company, today announced that Chief Scientific Officer M. Scot Roberts, PhD, will present at two premier vaccine conferences in the coming weeks. The first is Bacillus ACT 2015, the international conference on Bacillus anthracis, B. ceres & B. thuringiensis, to be held later this month in New Delhi, India

    Harvey Alter Receives 2015 Fries Prize for Improving Health
    ATLANTA, GA--(Marketwired - October 06, 2015) - Harvey Alter, M.D., M.A.C.P

    Novartis drug Afinitor® significantly improves progression-free survival in advanced nonfunctional gastrointestinal and lung NET
    Novartis International AG /Novartis drug Afinitor® significantly improves progression-free survival in advanced nonfunctional gastrointestinal and lung NET . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

    BioWatch's Alan Leong Interviewed by The Life Sciences Report
    SAN FRANCISCO, CA--(Marketwired - September 10, 2015) - CAR T-cell therapies show potential in treating acute myeloid leukemia (AML) and other medical conditions, but there's a lot of work to do before they're ready for commercialization

    GlobeImmune Announces Second Quarter 2015 Results and Corporate Highlights
    LOUISVILLE, CO--(Marketwired - August 14, 2015) - GlobeImmune, Inc. (NASDAQ: GBIM), a biopharmaceutical company focused on developing products for the treatment of cancer and infectious diseases based on its proprietary Tarmogen® platform, today announced its second quarter 2015 financial results and corporate highlights.

    GlobeImmune Engages Cantor Fitzgerald as Financial Advisor to Assist With Evaluation of Strategic Options
    LOUISVILLE, CO--(Marketwired - August 13, 2015) - GlobeImmune, Inc. (NASDAQ: GBIM), a biopharmaceutical company focused on developing products for the treatment of cancer and infectious diseases based on its proprietary Tarmogen® platform, announced today that it has engaged Cantor Fitzgerald & Co

    Galapagos on track to deliver on pipeline in second half 2015
    Half-year financial results 2015

    Vaxin First-in-Man Phase I Clinical Trial Initiated in Chronically Infected Hepatitis B Patients
    Vaxin Inc., a clinical stage vaccine and immunotherapeutics company, today announced that it has enrolled the first patient into a phase I clinical trial of HepTcell™ (FP-02.2), the company's immunotherapeutic compound to treat people chronically infected with the hepatitis B virus (HBV)

    Replicor Discloses Continued Improvement of the Antiviral Response in Patients with HBV / HDV Co-Infection Receiving REP 2139-Ca Based Combination Therapy
    Business Wire IndiaReplicor Inc

    Replicor Announces Publication of Its Pre-Clinical Data on the Therapeutic Effect of NAPs on Hepatitis B Virus Infection.
    Business Wire IndiaReplicor Inc

    Replicor Announces Grant of US Patents on HBV / HDV Treatment Methods Combining HBsAg Reduction and Immunotherapy
    Business Wire IndiaReplicor Inc

    Replicor Announces Initiation of Recruitment for Its Phase IIb Clinical Trial with REP 2139-Mg or REP 2165-Mg in Combination with Viread® and Pegasys® or Zadaxin® in Patients with HBeAg Negative Chronic Hepatitis B Infection
    Business Wire IndiaReplicor announces that the recruitment of patients is underway for its second Phase II trial in Caucasian patients that will assess the safety and antiviral efficacy of REP 2139-Mg or REP 2165-Mg in combination with Viread® and Pegasys® or Zadaxin® in patients with HBeAg negative chronic hepatitis B infection.

    SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Notifies Investors of Class Action Against Petroleo Brasileiro S.A. - Petrobras and Its Board of Directors and a Lead Plaintiff Deadline of February 6, 2015 -- PBR
    Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of investors who purchased Petroleo Brasileiro S.A. - Petrobras ("Petrobras" or the "Company") (NYSE: PBR) securities between May 20, 2010 and November 21, 2014.

    SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Barrett Business Services, Inc. and Certain Officers - BBSI
    Pomerantz LLP has filed a class action lawsuit against Barrett Business Services, Inc. ("Barrett" or the "Company") (NASDAQ: BBSI) and certain of its officers

    INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses in Excess of $100,000 Investing in Jumei International Holding Limited (JMEI) to Contact the Firm
    NEW YORK, NY--(Marketwired - December 17, 2014) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at Jumei International Holding Limited ("Jumei" or the "Company") (NYSE: JMEI).

    Novartis announces results of trial evaluating the use of Afinitor® in first-line treatment in HER2+ advanced breast cancer at SABCS
    Novartis International AG /Novartis announces results of trial evaluating the use of Afinitor® in first-line treatment in HER2+ advanced breast cancer at SABCS . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

    GlobeImmune Announces Third Quarter 2014 Financial Results
    LOUISVILLE, CO--(Marketwired - November 12, 2014) - GlobeImmune, Inc. (NASDAQ: GBIM), today announced its third quarter 2014 financial results and corporate highlights.

    SciClone Reports Financial Results for the Third Quarter 2014
    SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reported financial results for the third quarter 2014.

    SciClone to Present at Jefferies Global Healthcare Conference on November 19th
    SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that Friedhelm Blobel, Ph.D., Chief Executive Officer, will present a corporate overview and business update at the Jefferies Global Healthcare Conference on November 19, 2014, at 4:20 pm GMT, taking place at the Waldorf Hilton Hotel in London, England.

    SciClone Pharmaceuticals to Report Financial Results for the Third Quarter 2014 on November 10th
    SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it plans to report financial results for the third quarter 2014 on Monday, November 10, 2014. SciClone will host a conference call and webcast to provide a business and product update at 4:30 pm ET (1:30 pm PT) that day. The call will be hosted by Friedhelm Blobel, Ph.D., President and CEO, and Wilson W

    Revolutions Medical Donates 50,000 RevVac(TM) Auto-Retractable Vacuum Safety Syringes to the AmeriCares Foundation
    MOUNT PLEASANT, SC--(Marketwired - October 27, 2014) - Revolutions Medical Corporation (PINKSHEETS: RMCP) announces that it has donated 50,000 RevVac™ safety syringes to the AmeriCares Foundation. AmeriCares U.S. network is comprised of approximately 700 safety net health centers that serve uninsured or underinsured patients at more than 200% below the federal poverty level

    Updated Chordoma Data From Phase 1 Study of GI-6301 Presented at 2014 Connective Tissue Oncology Society (CTOS) Annual Meeting
    BERLIN, GERMANY--(Marketwired - October 17, 2014) - GlobeImmune, Inc., today announced that updated results from eleven chordoma patients in the GI-6301 Phase 1 trial were presented at the 2014 CTOS Annual Meeting in Berlin, Germany. Christopher R. Heery, M.D

    GlobeImmune to Present at the 13th Annual BioInvestor Forum
    LOUISVILLE, CO--(Marketwired - September 30, 2014) - GlobeImmune, Inc. (NASDAQ: GBIM) today announced that Timothy C. Rodell, M.D., Chief Executive Officer, will present at the 13th Annual BioInvestor Forum. Dr. Rodell will present at 9 a.m. PDT on Wednesday, Oct. 8, 2014, at the Palace Hotel in San Francisco, California.

    Novartis drug Afinitor is first treatment for advanced pancreatic NET to provide overall survival of more than 3.5 years in Phase III trial
    Novartis International AG /Novartis drug Afinitor is first treatment for advanced pancreatic NET to provide overall survival of more than 3.5 years in Phase III trial . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

    GlobeImmune to Present at the 21st Annual NewsMakers in the Biotechnology Industry Investment Conference
    LOUISVILLE, CO--(Marketwired - September 18, 2014) - GlobeImmune, Inc. (NASDAQ: GBIM) today announced that Timothy C. Rodell, M.D., Chief Executive Officer, will present at the 21st Annual BioCentury NewsMakers Conference. Dr. Rodell will present at 9:30 a.m. EDT on Sept. 26, 2014, at the Millennium Broadway Hotel and Conference Center in New York City.

    SciClone to Present at BioCentury NewsMakers in the Biotech Industry Conference on September 26, 2014
    SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that Friedhelm Blobel, PhD, Chief Executive Officer, will present a corporate overview and business update at the 2014 BioCentury NewsMakers in the Biotech Industry conference at 11:30 am ET on Friday, September 26, 2014, at the Millennium Broadway Hotel & Conference Center in New York City.

    GlobeImmune to Present at the Aegis Capital Corp. 2014 Healthcare Conference
    LOUISVILLE, CO--(Marketwired - September 03, 2014) - GlobeImmune, Inc. (NASDAQ: GBIM) today announced that Timothy C. Rodell, M.D., Chief Executive Officer, will present at the Aegis Capital Corp. 2014 Healthcare Conference in Las Vegas, Nevada. Dr. Rodell will present at 9:30 a.m. PDT on September 12, 2014, at The Encore at Wynn Las Vegas. 

    SciClone to Present at Aegis 2014 Healthcare & Technology Conference on September 11, 2014
    SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that Wilson W. Cheung, Chief Financial Officer, will present a corporate overview and business update at the Aegis Capital Corp. 2014 Healthcare & Technology Conference at 10:45 am PT on Thursday, September 11, 2014, at The Encore at Wynn in Las Vegas.

    SciClone and BTG Announce That DC Bead(R) Has Been Approved by China Food and Drug Administration
    SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN), and its partner BTG plc (LSE: BTG), today announced that the China Food and Drug Administration has approved the registration of DC Bead® for the embolization of malignant hypervascularized tumors.

    GlobeImmune Announces Second Quarter 2014 Financial Results
    LOUISVILLE, CO--(Marketwired - August 15, 2014) - GlobeImmune, Inc. (NASDAQ: GBIM) today announced its second quarter 2014 corporate highlights and financial results. The net loss for the second quarter was $5.7 million, bringing the net loss for the year to $8.2 million

    BioNet Appoints New COO and Accelerates the Development of New Recombinant Pertussis Vaccine
    BioNet-Asia, a vaccine company focused on vaccine discovery and supply, announced that Georges Thiry has been appointed COO of the company, effective early 2015.

    BioNet Provides Update on Recombinant Acellular Pertussis Vaccine at BioJapan 2014
    BioNet-Asia's CEO, Dr Pham Hong Thai provided today an update on the company lead vaccine program in his presentation at BioJapan 2014. Dr Pham said that the current Phase I/II trial in Thailand showed that the vaccine is safe and immunogenic and full results will soon be published in a peer reviewed journal

    Rosetta Genomics Granted U.S. Patent Allowance for the Use of microRNAs to Treat Liver Cancer
    Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces receipt of a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) related to U.S. Patent Application No. 13/481,105 titled "Targeting microRNAs for the Treatment of Liver Cancer."

    Medical Cannabis Financial Group, Inc. Announces Merger Transaction With Refill Energy, Inc.
    Refill Energy, Inc. (PINKSHEETS: REFG), a Nevada Corporation (the "Company") announces the merger between Refill Energy, Inc. and Medical Cannabis Financial Group. Refill Energy, Inc. completed a reorganization with Medical Cannabis Financial Group, Inc., which is a software solutions company focused on solutions for the Medical Marijuana industry

    Novartis to highlight long-term data, innovative pipeline for patients with hematologic diseases and breast cancer at ASH and SABCS
    Novartis International AG /Novartis to highlight long-term data, innovative pipeline for patients with hematologic diseases and breast cancer at ASH and SABCS . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

    SciClone to Present at Oppenheimer Healthcare Conference on December 10, 2013
    SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that Friedhelm Blobel, Ph.D., Chief Executive Officer, will present a corporate overview and business update at the Oppenheimer 24th Annual Healthcare Conference on Tuesday, December 10, 2013, at 3:20 pm ET at the Crowne Plaza Hotel in New York.

    SCYNEXIS Appoints Vivian Doelling as Vice President of Animal Health
    Drug discovery company SCYNEXIS, Inc. today announced the appointment of Dr. Vivian Doelling as Vice President of Animal Health. Doelling is an industry leader in the field of animal health with more than 20 years of experience.

    SciClone Reports Financial Results for the Three and Nine Months Ended September 30, 2013
    SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reported financial results for the third quarter and for the nine months ended September 30, 2013.

    Fuzheng Huayu (FZHY) Completed Phase II Clinical Trial for Treatment of Liver Fibrosis in Patients With Chronic Hepatitis C
    Shanghai Sundise Traditional Chinese Medicine Co. Ltd today released its multi-center, double-blinded, placebo-controlled clinical phase II trial results at a satellite symposium during the 2013 annual meeting of American Association for Study of Liver Diseases (AASLD®)

    SciClone Pharmaceuticals to Report Financial Results for the Third Quarter, 2013 on November 12th
    SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it plans to report financial results for the third quarter, 2013 on Tuesday, November 12, 2013. SciClone will host a conference call and webcast to provide a business and product update at 8:30 am ET that day. The call will be hosted by Friedhelm Blobel, Ph.D., President and CEO, and Wilson W

    GlobeImmune Announces Presentation of GI-4000 Phase 2 Data at IASLC World Conference on Lung Cancer
    Sydney, Australia, October 28, 2013 - GlobeImmune, Inc. announced that data from a Phase 2 clinical trial of the GI-4000 Tarmogen® in patients with non-small cell lung cancer (NSCLC) will be presented today at the International Association for the Study of Lung Cancer (IASLC) 15th World Conference on Lung Cancer in Sydney, Australia

    GlobeImmune Announces Milestone Payment for Initiation of Phase 2 Clinical Trial for GS-4774 (Formerly GI-13020) in Patients with Chronic Hepatitis B Virus Infection
    LOUISVILLE, Colo., October 15, 2013 - GlobeImmune, Inc., today announced that it has earned a milestone payment from Gilead Sciences, Inc

    SciClone Appoints Nancy T. Chang, Ph.D., to Its Board of Directors
    SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that Nancy T. Chang, Ph.D., has been appointed a member of the Company's board of directors. Dr. Chang has more than 30 years of experience in the pharmaceutical and biotechnology industry, and has successfully developed and commercialized multiple therapeutic and diagnostic products

    SciClone to Present at Four Investor Conferences in September 2013
    SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that the Company will present a corporate overview and business update at four upcoming investor conferences in September 2013.

    GlobeImmune Awarded $4 Million NIH Grant to Develop Tarmogens for the Treatment of Tuberculosis
    LOUISVILLE, Colo., September 4, 2013 - GlobeImmune, Inc., announced today that it has been awarded a $4 million Research Project Grant (R01) by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) to support the development of Tarmogen® immunotherapy products to treat and prevent tuberculosis infection.

    Bio Farma Launches Pentavalent Vaccine, Combining Five Antigens
    The Indonesian Ministry of Health will introduce a new immunization program, and a pentavalent vaccine for babies aged 2 months to 1 year. One shot of the pentavalent vaccine will prevent babies from five diseases at once, including Diphtheria, Tetanus, Pertussis, Hepatitis B and Haemophilus influenzae Type B.The pentavalent vaccine, produced by Bio Farma, has been in development since 2007

    Regen BioPharma Inc. Licenses Cancer Gene Silencing Technology From Benitec BioPharma
    Bio-Matrix Scientific Group Inc. (OTCQB: BMSN) announced today that its wholly owned subsidiary, Regen BioPharma Inc. executed a license agreement with the clinical stage biotechnology company, Benitec Biopharma Ltd. (ASX: BLT) for the development of vaccines using Benitec's ddRNAi gene silencing technology.

    SciClone Pharmaceuticals to Report Financial Results for the Three and Six Months Ended June 30, 2013 on August 7th
    SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it plans to report financial results for the three and six months ended June 30th, 2013 on Wednesday, August 7, 2013. SciClone will host a conference call and webcast to provide a business and product update at 8:30 am ET that day. The call will be hosted by Friedhelm Blobel, Ph.D., President and CEO, and Wilson W

    SciClone Appoints Wilson W. Cheung as Chief Financial Officer
    SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced the appointment of Wilson W. Cheung as Chief Financial Officer and Senior Vice President, Finance. Mr

    PURE Bioscience Completes Successful Field Test of PURE Hard Surface Disinfectant With Leading Quick Service Restaurant Chain
    PURE Bioscience, Inc. (OTCQB: PURE), the creator of the patented silver dihydrogen citrate (SDC) antimicrobial, successfully completed in-store field testing of its PURE® Hard Surface disinfectant/sanitizer by a leading worldwide quick service restaurant chain.

    SciClone and Taiwan Liposome Company Enter Into a Licensing Agreement for ProFlow(R), a Novel Treatment for Peripheral Arterial Disease for the China Market
    SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that the Company has entered into an agreement with Taiwan Liposome Company (TLC) granting SciClone a license and the exclusive rights in China, Hong Kong and Macau to promote, market, distribute and sell ProFlow® for the treatment of peripheral arterial disease (PAD) and other indications.

    36 Year Old Undergoes 16 Hour Liver Transplant Surgery at HCG, Gets a New Lease of Life
    HCG Hospitals, organized a press conference on treating 36 year old Indian from USA, diagnosed with liver cirrhosis, underwent marathon 16 hour liver transplant surgery, with the organ donated from his wife. A year ago, the patient had weakness and loss of appetite. During his routine health check-ups, he was diagnosed with liver cirrhosis, due to autoimmune hepatitis

    As Competitors Pursue Alternatives Medgenics' INFRADURE Gains Prominence for its Potential to Treat Hepatitis
    Medgenics' (NYSEAMEX: MDGN) INFRADURE(TM) provides sustained productionand delivery of interferon-alpha for the treatment of hepatitis. INFRADURE(TM) is a kind of miniature pump that is impacted into the patient and continuously produces and release the desired protein into the patient's system

    Melbourne University and Bio Farma to Jointly Develop Vaccine Adjuvant
    Melbourne University has announced an agreement with Indonesian vaccine maker Bio Farma to develop a vaccine delivery system that can boost the vaccine effectiveness for a range of infectious diseases, including Hepatitis C, Diphtheria, Tetanus, Pertussis, Hepatitis B and Haemopilus influenza type-B."Bio Farma is proud to collaborate with the University of Melbourne

    SciClone to Present at Oppenheimer 23rd Annual Healthcare Conference on December 13th
    SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that Friedhelm Blobel, Chief Executive Officer, will present a corporate overview and business update at the Oppenheimer 23rd Annual Healthcare Conference on December 13, 2012 at 11:10 am ET at the Waldorf-Astoria Hotel in New York City.

    SciClone Announces New ZADAXIN(R) Anti-Counterfeiting Label Wins Major Industry Award
    SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that its newly created anti-counterfeiting Pharma-Comb Void label for ZADAXIN has won the prestigious "Innovator Award" in the annual competition sponsored by the Tag and Label Manufacturers Institute (TLMI)

    Novartis highlights key data in patients with hematologic diseases and breast cancer with more than 140 abstracts at ASH and SABCS
    Novartis International AG /Novartis highlights key data in patients with hematologic diseases and breast cancer with more than 140 abstracts at ASH and SABCS . Processed and transmitted by Thomson Reuters ONE.The issuer is solely responsible for the content of this announcement.

    SciClone to Present at Lazard Capital Markets 9th Annual Healthcare Conference on November 14th
    SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that Gary Titus, Chief Financial Officer, will present a corporate overview and business update at the Lazard Capital Markets 9th Annual Healthcare Conference on November 14, 2012 at 2:00 pm ET at the Pierre Hotel in New York City.

    GI-5005 Improves Virologic Clearance of HCV in Combination with PegIFN/Ribavirin in IL28B T/T Patients
    Clinical Trial Data to be Presented at The Liver Meeting® 2012 in BostonBOSTON, Nov. 11, 2012 - GlobeImmune, Inc

    GI-13020 Tarmogen® for the Treatment of Chronic Hepatitis B Generates Antigen-specific T Cell Responses in Key Preclinical Studies
    Data to be Presented Today at The Liver Meeting® 2012 in BostonBOSTON, Nov. 10, 2012 - GlobeImmune, Inc. today announced that GI-13020, an investigational therapeutic vaccine designed using the company's proprietary Tarmogen® product platform for the treatment of chronic hepatitis B virus (HBV) infection, demonstrated immunogenicity in two preclinical studies

    SciClone Reports Financial Results for the Third Quarter 2012 and 2012 Outlook
    SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reported financial results for the third quarter and for the nine months ended September 30, 2012

    Direction Change Ahead, What to Expect - Research & Analysis on Marathon Oil Corporation and Marathon Petroleum Corporation
    Moments ago, TradersInsight.net introduced new coverage of Marathon Oil Corporation (NYSE: MRO) and Marathon Petroleum Corporation (NYSE: MPC). Full outlook, analysis and consensus opinion is available to readers via the links below.

    SciClone Pharmaceuticals to Report Financial Results for the Third Quarter 2012 and 2012 Outlook on November 9th
    SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it plans to report third quarter 2012 financial results and 2012 outlook on Friday, November 9, 2012. SciClone will host a conference call and webcast to provide a business and product update at 8:30 am ET that day. The call will be hosted by Friedhelm Blobel, Ph.D

    Novartis drug Votubia® approved in the EU as first medication to treat patients with non-cancerous kidney tumors associated with TSC
    Novartis International AG /Novartis drug Votubia® approved in the EU as first medication to treat patients with non-cancerous kidney tumors associated with TSC . Processed and transmitted by Thomson Reuters ONE.The issuer is solely responsible for the content of this announcement.

    NuPathe Announces Closing of $28 Million Private Placement and Changes to Its Board of Directors
    NuPathe Inc. (NASDAQ: PATH), a specialty pharmaceutical company focused on the development and commercialization of branded therapeutics for diseases of the central nervous system, today announced the closing of its previously disclosed $28 million sale of securities

    Delcath Announces CE Marking for Hepatic CHEMOSAT(R) Delivery System for Use with Doxorubicin Injection
    Delcath Systems, Inc. (NASDAQ: DCTH) today announced that the Company has satisfied all of the requirements to affix the CE Mark to its Hepatic CHEMOSAT(R) Delivery System for use with doxorubicin hydrochloride injection. Doxorubicin is an established chemotherapeutic agent commonly used globally to treat hepatocellular carcinoma (HCC) via trans-arterial chemoembolization (TACE)

    Benitec Announces Acquisition of Tacere Therapeutics and Phase I/II Ready Hepatitis C (HCV) Program
    Benitec Biopharma (ASX: BLT)

    Novartis drug Votubia® recommended by CHMP for EU approval to treat patients with non-cancerous kidney tumors associated with TSC
    Novartis International AG /Novartis drug Votubia® recommended by CHMP for EU approval to treat patients with non-cancerous kidney tumors associated with TSC . Processed and transmitted by Thomson Reuters ONE.The issuer is solely responsible for the content of this announcement.

    SciClone Announces China Government-Mandated ZADAXIN(R) Price Reduction; Anticipates Minimal Impact on Revenue and Margins
    SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that consistent with the China government's review of pharmaceutical prices once a product has been included into the Reimbursement Drug List ("RDL"), the retail list price, or hospital pharmacy level price, of ZADAXIN® has been reduced by about 18% in China

    SciClone Announces Management Transitions in China Operations
    SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that Mark Lotter will resign from the position of Chief Executive Officer of SciClone's China Operations at the end of this year and plans to relocate from Shanghai to London in order to spend more time with his family. At that time Mr. Lotter will also resign his position as a director of the Company.

    Market Influences That Drive Equities Forward -- Industry Report on Lorillard, Inc and Philip Morris International Inc
    Moments ago, DividendSeeker.net introduced new coverage of Lorillard, Inc (NYSE: LO) and Philip Morris International Inc (NYSE: PM). Full outlook, analysis and consensus opinion is available to readers via the links below.

    SCYNEXIS’ Oral SCY-635 Shows Potential as an Immune Acting Antiviral to Augment Current HCV Treatments
    SCYNEXIS, Inc

    Dynavax Initiates Proof of Mechanism Trial in Lupus Patients
    Dynavax Technologies Corporation (NASDAQ: DVAX) announced today the initiation of a proof-of-mechanism clinical trial of the TLR7 and TLR9 inhibitor, DV1179, in systemic lupus erythematosus (SLE) patients. Initiation of this trial entitles Dynavax to receive a $6 million milestone payment from GlaxoSmithKline (GSK) under their worldwide strategic alliance

    SciClone Pharmaceuticals Announces Final Settlement of Stockholder Derivative Litigation
    SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that the California Superior Court for the County of San Mateo has granted final approval of a settlement reached by the parties to the consolidated derivative lawsuits against certain of its current and former directors and officers of SciClone Pharmaceuticals, and against SciClone as a nominal defendant.

    New data confirms Novartis drug Afinitor® significantly extends time women with advanced breast cancer live without tumor growth
    Novartis International AG /New data confirms Novartis drug Afinitor® significantly extends time women with advanced breast cancer live without tumor growth . Processed and transmitted by Thomson Reuters ONE.The issuer is solely responsible for the content of this announcement.

    Novartis highlights advances for patients with breast cancer and hematological diseases with over 160 SABCS and ASH abstracts
    Novartis International AG /Novartis highlights advances for patients with breast cancer and hematological diseases with over 160 SABCS and ASH abstracts . Processed and transmitted by Thomson Reuters ONE.The issuer is solely responsible for the content of this announcement.

    SciClone Pharmaceuticals Added to the NASDAQ Biotechnology Index
    SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that the Company will be added to the NASDAQ Biotechnology Index® (NASDAQ: NBI). The semi-annual re-ranking of the index will become effective prior to market opening on Monday, November 21, 2011.

    Nail salons and barbershop could up hepatitis transmission risk
    According to a new report, the risk of contracting hepatitis from reusable instruments used in nail salons and barbershop visits cannot be excluded.

    Pak pacer Sadaf Hussain says he 'wanted to give up cricket' following mother's death
    Sadaf Hussain, who was part of the Pakistan team for the Caribbean tour, has said that he 'wanted to give up cricket for good' following his mother's demise.

    Scientists claim viruses may cause up to 40pc of cancers
    Viruses may be behind up to 40 per cent of cancers including brain tumours and leukaemia, according to scientists.

    Sharks 'to protect us from dengue, yellow fever, and hepatitis'
    Scientists have found that a compound initially isolated from sharks could be used as a unique broad-spectrum human antiviral agent against human viruses ranging from dengue and yellow fever to hepatitis B, C, and D.

    Azad reaffirms India's commitment to complete polio eradication
    Union Health and Family Welfare Minister Ghulam Nabi Azad was honoured yet again by Rotary International as a Champion in Worldwide Efforts to Eradicate Polio.

  • Comment on this story

    Share